FSN's subsidiary, Boosters, GIPUN has surpassed its target funding amount by over 2,000% on Wadiz.


GIPUN Neoshot Skin Boost Serum. Boosters

GIPUN Neoshot Skin Boost Serum. Boosters

View original image

According to Boosters on the 5th, the brand has accumulated more than 100 million won in total funding and attracted a total of 1,480 supporters. Through this, they have established an initial customer base and accumulated product reviews and consumer response data, which will be used for future brand operations.


Boosters positioned this Wadiz funding as a core process for verifying the brand and securing initial loyal customers, going beyond a simple sales event. The process included conducting product tester operations, actual purchases, and gathering reviews, which allowed for step-by-step consumer validation. The customer data and feedback collected through this process are planned to be reflected in future product improvement and marketing strategy formulation.


Based on the market response confirmed through the Wadiz funding, Boosters will begin expanding its distribution network in earnest in August. The brand is preparing to enter major domestic commerce channels, including Naver Smart Store, while also preparing for an official launch on Amazon in North America. Additionally, through a pre-launch on their own website, the company intends to pre-validate the brand message and consumer response and apply these findings to its actual sales strategy.



A representative from Boosters stated, "Wadiz funding was not only an opportunity to secure initial customers, but also to confirm the positive market response to GIPUN's brand concept and product competitiveness. Based on the customer data and accumulated reviews obtained through this funding, we plan to rapidly expand our business to major domestic commerce platforms and Amazon in North America."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing